

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 January 2022 (06.01.2022)



(10) International Publication Number
WO 2022/006331 A3

(51) International Patent Classification:

A61K 31/506 (2006.01) A61K 31/52 (2006.01)
A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2021/039982

(22) International Filing Date:

30 June 2021 (30.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/046,325 30 June 2020 (30.06.2020) US

(71) Applicant: **4E THERAPEUTICS, INC.** [US/US]; Dell Medical School-Health Discovery Bldg., 1601 Trinity Street, Bldg. B Z1400, Austin, Texas 78712 (US).

(72) Inventors: **PRICE, Theodore J.**; c/o 4E Therapeutics, Inc., Dell Medical School-Health Discovery Bldg., 1601 Trinity Street, Bldg. B Z1400, Austin, Texas 78712 (US). **SAHN, James J.**; c/o 4E Therapeutics, Inc., Dell Medical School-

Health Discovery Bldg., 1601 Trinity Street, Bldg. B Z1400, Austin, Texas 78712 (US).

(74) Agent: **LIGON, Toby J.** et al.; Seed Intellectual Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: PYRIDINE-1,5-DIONES EXHIBITNG MNK INHIBITION AND THEIR METHOD OF USE





FIG. 1



(57) Abstract: Compounds having activity as inhibitors of MNK are provided. One embodiment provides compounds having Structure (II): Formula (II) or a pharmaceutically acceptable salt, stereoisomer, tautomer, or prodrug thereof, wherein R^{1a} , R^{1b} , R^2 , X, Y, and L are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of MNK are also provided.

[Continued on next page]

WO 2022/006331 A3

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

10 February 2022 (10.02.2022)